Latest Breaking News On - Strontium chloride - Page 5 : vimarsana.com

Strontium89 Now Reimbursed in Hospital and Outpatient Settings for Metastatic Bone Pain Treatment Strontium89 Now Reimbursed in All Treatment Settings News provided by Share this article NEW YORK, Jan. 7, 2021 /PRNewswire/ Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that the Centers for Medicare and Medicaid Services (CMS) updated the Outpatient Prospective Payment System (OPPS) reimbursement rate for its FDA approved non-opioid metastatic bone pain drug Strontium89 (Strontium Chloride Sr-89 Injection, USP) on January 3, 2021. The update ensures all Medicare patients have access to Strontium89 in the appropriate setting. The Q1 2021 Strontium89 reimbursement update was expected by Q BioMed as part of the standard CMS quarterly OPPS update, and is an important milestone. While Strontium89 has been appropriately reimbursed in the free standing clinic setting since launch, it was under-reimbursed in the hospital outpatient setting where

Denis corinKeith pinderCenters for medicareSecurities exchangeCq biomed incMedicaid servicesSourceq biomed incIsotherapeutics groupOutpatient prospective payment systemStrontium chlorideImportant safety informationAbiomed incLooking statementsSecurities actSecurities exchange actBiomed media contact